RxSight (NASDAQ:RXST) Given New $10.00 Price Target at Piper Sandler

RxSight (NASDAQ:RXST) had its target price trimmed by Piper Sandler from $11.00 to $10.00 in a research note issued to investors on Thursday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

RXST has been the topic of a number of other research reports. Wolfe Research raised RxSight to an “outperform” rating in a research report on Friday, January 30th. Morgan Stanley boosted their price objective on shares of RxSight from $9.00 to $10.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. JPMorgan Chase & Co. raised their target price on shares of RxSight from $8.00 to $9.00 and gave the company an “underweight” rating in a research report on Thursday, November 6th. Stifel Nicolaus set a $10.00 price target on shares of RxSight in a research note on Thursday, November 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $13.00 price objective on shares of RxSight in a research note on Thursday. Two research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, RxSight currently has an average rating of “Reduce” and an average target price of $9.89.

RxSight Price Performance

RXST opened at $7.92 on Thursday. The company has a market capitalization of $325.67 million, a price-to-earnings ratio of -8.34 and a beta of 1.14. The business’s 50-day moving average price is $9.44 and its two-hundred day moving average price is $9.48. RxSight has a 1 year low of $6.32 and a 1 year high of $29.69.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of RXST. Raymond James Financial Inc. acquired a new position in shares of RxSight during the 2nd quarter worth about $28,000. Bessemer Group Inc. bought a new position in RxSight during the second quarter worth about $33,000. Larson Financial Group LLC increased its position in RxSight by 110.5% during the third quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock worth $36,000 after buying an additional 2,089 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its stake in RxSight by 440.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company’s stock valued at $39,000 after buying an additional 3,063 shares during the period. Finally, CWM LLC lifted its position in shares of RxSight by 211.1% in the fourth quarter. CWM LLC now owns 3,826 shares of the company’s stock valued at $40,000 after buying an additional 2,596 shares during the last quarter. Institutional investors own 78.78% of the company’s stock.

RxSight News Summary

Here are the key news stories impacting RxSight this week:

• Positive Sentiment: Q4 results beat expectations: RxSight reported GAAP EPS of ($0.03) vs. the consensus loss of ($0.25) and revenue of $32.61M roughly in line with estimates — an earnings beat that limits downside. Zacks: Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: UBS raised its price target from $8 to $9 while keeping a neutral rating, showing modest analyst support for upside from current levels. Benzinga: UBS Raises PT
• Neutral Sentiment: Piper Sandler lowered its target from $11 to $10 but maintained a neutral rating — a mixed signal that modestly reduces implied upside. Benzinga: Piper Sandler Lowers PT
• Neutral Sentiment: Company posted Q4/2025 earnings call transcripts and additional disclosures (useful for detail but not a directional catalyst by itself). Yahoo: Q4 2025 Earnings Call Transcript Seeking Alpha: Transcript
• Negative Sentiment: FY‑2026 revenue guidance came in at $120M–$135M versus a Street consensus near $135.4M — a guide that sits at or below expectations and is the primary near‑term negative catalyst. Business Insider: Q4 & 2026 Guidance
• Negative Sentiment: Revenue is down ~18.9% year‑over‑year and the company reported negative margins and ROE — signs of operating pressure that could weigh on valuation until growth stabilizes. MarketBeat: Earnings Summary
• Negative Sentiment: Short interest rose materially in February to ~14.4% of shares outstanding (days-to-cover ~4.7), increasing downside selling pressure and volatility risk — though it also raises short‑squeeze potential.

RxSight Company Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.